Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

October 12, 2022

Study Completion Date

October 12, 2022

Conditions
Retinitis PigmentosaUsher Syndrome Type 2Deaf BlindRetinal DiseaseEye DiseasesEye Diseases, HereditaryEye Disorders CongenitalVision Disorders
Interventions
DRUG

Ultevursen

RNA antisense oligonucleotide for intravitreal injection

OTHER

Sham-procedure

Sham-procedure (no experimental drug administered)

Trial Locations (15)

10032

Columbia University, New York

21287

Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore

30322

Emory Eye Center, Atlanta

33136

University of Miami, Bascom Palmer Eye Institute, Miami

48105

University of Michigan, Kellogg Eye Center, Ann Arbor

53705

University of Wisconsin - Madison, Madison

72076

Universitaetsklinikum Tuebingen Department für Augenheilkunde, Tübingen

75231

Retina Foundation of the Southwest, Dallas

94158

University of California, San Francisco, San Francisco

92093-0946

Shiley Eye Institute - UC San Diego, San Diego

02114

Center for Clinical Research Operations, Massachusetts Eye and Ear, Boston

6525 GA

RadboudUMC, Nijmegen

3011 BH

Het Oogziekenhuis Rotterdam, Rotterdam

OX3 9DU

Oxford Eye Hospital, Headington

Unknown

Moorfields Eye Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Sepul Bio

INDUSTRY

lead

Laboratoires Thea

INDUSTRY